This post was originally published on this site
(Corrects spelling of company in first paragraph)
(Reuters) – Johnson & Johnson (NYSE:JNJ) said on Tuesday it will acquire medical technology provider Abiomed (NASDAQ:ABMD) Inc for an upfront payment of $380 per share in cash, corresponding to an enterprise value of nearly $16.6 billion.
